Is a complete AGMB research report available?

No complete published report is available for AgomAb Therapeutics NV (AGMB) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

AgomAb Therapeutics NV (AGMB)

NASDAQ: AGMB · USD

$12.5

-0.43 (-3.3%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AGMB analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	617.6M
Net income (ttm)	-91M
EPS (ttm)	-$168
Shares out	49.2M
Volume	59,096
Price target	$32.8	+161.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -91M
EPS (ttm): -$168
Market cap: 617.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AGMB indicators

Market & fundamental data

Available fields

155

Groups with data

Currency

EUR

Showing 155 of 155 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002020932
Company name	AgomAb Therapeutics NV
Country	Belgium
Country code	US
Cusip	00860C102
Employees	62
Employees Change	4.2%
Employees Change Percent	7.27
Enterprise value	$480.8M
Exchange	NASDAQ
Financial currency	EUR
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-02-06
Isin	US00860C1027
Last refreshed	2026-07-25
Market cap	$617.6M
Market cap category	Small-Cap
Price	$12.54
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.59
Sic	2836
Symbol	AGMB
Tags	pharmaceuticals
Website	https://www.agomab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-14.77%
FCF yield	-9.55%
P/B ratio	4.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-91M
Net Income Growth Years	0%
Profit Per Employee	$-1.5M
ROA	-20.58
ROCE	-42.49
ROE	-39.22
ROIC	-23.03

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$180.5M
Cash	$136.8M
Current Assets	$137.9M
Current Liabilities	$21.1M
Debt	$1.5M
Debt Equity	$0.01
Equity	$153.7M
Interest Coverage	-956.8
Liabilities	$26.8M
Long Term Assets	$42.6M
Long Term Liabilities	$5.6M
Net Cash	$135.3M
Net Cash By Market Cap	$21.97
Net Debt Equity	$-0.88
Tangible Book Value	$-231.9M
Tangible Book Value Per Share	$-4.71

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.52
Net Working Capital	$-16M
Quick ratio	6.49
Working Capital	$120.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	11.75
All Time High	17.82
All Time High Change	-29.63%
All Time High Date	2026-06-29
All Time Low	8.75
All Time Low Change	43.31%
All Time Low Date	2026-06-08
ATR	1.22
Beta1y	1.24
High	13.12
High52	17.82
High52 Date	2026-06-29
High52ch	-29.63%
Low	12.36
Low52	8.75
Low52 Date	2026-06-08
Low52ch	43.31%
Ma50ch	6.77%
RSI	51.49
RSI Monthly	0
RSI Weekly	49.11
Sharpe ratio	0.1x
Sortino ratio	0.2
Tr1m	5.03%
Tr1w	4.15%
Tr3m	17.2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	3
Analyst Price Target Top	$34.33
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.39
Operating Income	$-69.6M
Price target	$32.75
Price Target Change	$161
Price Target Change Top	$174

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	16,413,633%
Float Percent	33.33%
Net Borrowing	-384,335.9
Shares Insiders	0.09%
Shares Institutions	44.33%
Shares Out	49,247,975
Shares Qo Q	0%
Short Ratio	9.5
Short Shares	3.05

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-65.1M
Average Volume	97,987x
Bv Per Share	-4.02
CAPEX	$-4,696
Ch1m	5.03
Ch1w	4.15
Ch3m	17.2
Change	-3.32%
Change From Open	-2.64
Close	12.97
Days Gap	-0.69
Depreciation Amortization	457,868
Dollar Volume	741,063.8
Earnings Date	2026-09-17
Earnings Time	bmo
EBIT	$-67.4M
EBITDA	$-67.2M
EPS	$-168
F Score	2
FCF	$-58.8M
FCF EV Yield	-12.24x
FCF Per Share	$-1.19
Financing CF	-396,853
Fiscal Year End	December
Founded	2,017
Goodwill	9,792,606.4
Investing CF	-38,750,734
Ipr	-21.63
Iprfo	-14.69
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-23
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-04-23
Ma20	12.84
Ma20ch	-2.34%
Net CF	-99,845,016
Next Earnings Date	2026-09-17
Open	12.88
Optionable	No
Position In Range	23.68
Post Close	12.54
Postmarket Change Percent	-0.24
Postmarket Price	$12.51
Ppne	1,803,422.4
Price Date	2026-07-24
Relative Volume	0.6x
Share Based Comp	6,287,425
Volume	59,096

AgomAb Therapeutics NV (AGMB)

Coverage state: Market snapshot only — no published research

Generate the first AGMB analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AGMB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AGMB indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AGMB

Frequently asked questions